SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Availability of and Access to Orphan Drugs
8 references·1 citing·37 second hop
Availability of and Access to Orphan Drugs (2010)Availability of and Access to Orphan DrugsMarket incentives and pharmaceutical innovation (2008)Market incentives and pharmac…Incentives for orphan drug research and development in the United States (2008)Incentives for orphan drug re…Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Assessing the economic challenges posed by orphan drugs (2007)Assessing the economic challe…Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products (2006)Are rare diseases still orpha…Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases (2006)Adopting Orphan Drugs — Two D…AfDB Group Annual Report 2004 (2005)AfDB Group Annual Report 2004Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Prices And Availability Of Ph…Patient Access to Medicines for Rare Diseases in European Countries (2018)Patient Access to Medicines f…Two decades of orphan product development (2002)Drugs for exceptionally rare diseases: do they deserve special status for funding? (2005)Orphan drugs and the NHS: should we value rarity? (2005)Translation of rare disease research into orphan drug development: disease matters (2009)A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study (2010)Access to orphan drugs despite poor quality of clinical evidence (2010)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases (2013)Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases (2021)Stability in Competition (1929)MONOPOLISTIC COMPETITION AND OPTIMUM PRODUCT DIVERSITY (1975)Stability in Competition (1990)The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? (2009)Economics of the Pharmaceutical Industry (2018)Cost of innovation in the pharmaceutical industry (1991)The price of innovation: new estimates of drug development costs (2003)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)The High Cost of Cancer Drugs and What We Can Do About It (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)A Contribution to the Theory of Taxation (1927)Cross-national price differences for pharmaceuticals: how large, and why? (2000)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)International Prices And Availability Of Pharmaceuticals In 2005 (2008)Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States (2014)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)National Institute for Clinical Excellence and its value judgments (2004)Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (2015)Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years (2010)Policies and Incentives for Promoting Innovation in Antibiotic Research (2010)Assessment of operational and environmental performance of the thermal power plants in Turkey by using data envelopment analysis (2010)Financial liberalization, exchange rates and stock prices: Exogenous shocks in four Latin America countries (2010)China as a Final Market: The Gabon Timber and Thai Cassava Value Chains (2011)
this work references cited by second hop

References

  • 2007Economics of New Oncology Drug Development348 cited
  • 2007Assessing the economic challenges posed by orphan drugs279 cited
  • 2003Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries199 cited
  • 2008Market incentives and pharmaceutical innovation189 cited
  • 2006Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases162 cited
  • 2008Incentives for orphan drug research and development in the United States138 cited
  • 2006Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products88 cited
  • 2005AfDB Group Annual Report 200419 cited

Cited by

  • 2018Patient Access to Medicines for Rare Diseases in European Countries76 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work